The present invention relates to the discovery that inhibition of the interaction between Dickkopf 2 (DKK2) and Low-Density Lipoprotein (LDL) Receptor Related Protein 5 (LRP5) and/or inhibition of LRP5 suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of an inhibiting agent that blocks the interaction between DKK2 and LRP5, methods of treating cancer by administering to a patient an effective amount of a LRP5 depleting agent, methods for providing anti-tumor immunity in a subject, and methods of stimulating a NK and T cell mediated immune response to a cell population or a tissue in a subject. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer.本發明係關於抑制Dickkopf2(DKK2)和低密度脂蛋白(LDL)受體相關蛋白5(LRP5)之間的交互作用及/或抑制LRP5以遏止腫瘤形成。因此，在本文所述的各種實施例中，本發明的方法涉及透過向患者施用有效劑量的抑制劑，以阻斷DKK2和LRP5之間的相互作用來治療癌症的方法、透過向患者施用有效劑量的LRP5剔除試劑以治療癌症的方法、在受試者中提供抗腫瘤免疫的方法，以及在受試者中激發對細胞群或組織的NK和T細胞介導免疫反應的方法。此外，本發明包括用於治療癌症的醫藥組合物。
